Search - tctmd.com

Displaying 261 - 280 of 342

Sort: Relevancy | Date

Presentation TCT 2015

DAPT Duration Case 1: An Elderly Patient With CKD and Left Main Bifurcation Stenting In-Hospital Course

Presenter: John A. Bittl, Gary L. Schaer, Gennaro Giustino

October 12, 2015

Presentation TCT 2015

Is Dropping Aspirin the Magic Solution?

Presenter: John A. Bittl, Gary L. Schaer, Pascal Vranckx

October 12, 2015

Presentation TCT 2015

Risk vs Benefit: Can We Determine Which Patients Should Be Treated With Long-term DAPT?

Presenter: John A. Bittl, Gary L. Schaer, Matthew T. Roe

October 12, 2015

Presentation TCT 2015

Does PEGASUS Inform the Debate?

Presenter: John A. Bittl, Gary L. Schaer, Stephen D. Wiviott

October 12, 2015

Presentation TCT 2015

Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most!

Presenter: John A. Bittl, Gary L. Schaer, Tullio Palmerini

October 12, 2015

Presentation TCT 2015

Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most!

Presenter: John A. Bittl, Gary L. Schaer, Laura Mauri

October 12, 2015

Presentation TCT 2015

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Statistical Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Stuart J. Pocock

October 12, 2015

Presentation TCT 2015

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Clinical/Trialist Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Gregg W. Stone

October 12, 2015

Presentation TCT 2015

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All?

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

Presentation TCT 2015

Three to Six Months of DAPT Is My Practice Even in Very Complex Cases: Heres Why

Presenter: Ricardo Lluberas, Roxana Mehran, Jamil Abdalla Saad, Fausto Feres

October 11, 2015

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Presentation TCT 2015

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Presenter: John A. Bittl, E. Magnus Ohman, James B. Hermiller Jr

October 11, 2015

Presentation TCT 2015

Debate: The Case for Short-term DAPT in Most Patients!

Presenter: Regina Deible, Gennaro Giustino

October 11, 2015

Presentation TCT 2015

Featured Lecture: New DAPT Duration Recommendations

Presenter: John A. Bittl, E. Magnus Ohman

October 11, 2015

Presentation TCT 2015

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Presenter: Regina Deible, Daniel I. Simon

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon

October 11, 2015

Advertisement

DAPT Duration Case 1: An Elderly Patient With CKD and Left Main Bifurcation Stenting In-Hospital Course

Is Dropping Aspirin the Magic Solution?

Risk vs Benefit: Can We Determine Which Patients Should Be Treated With Long-term DAPT?

Does PEGASUS Inform the Debate?

Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most!

Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most!

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Statistical Perspective

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Clinical/Trialist Perspective

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

DAPT Duration After DES: Does 1 Size Fit All?

DAPT Study Subanalysis Focuses on EES Subgroup

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Three to Six Months of DAPT Is My Practice Even in Very Complex Cases: Heres Why

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Debate: The Case for Short-term DAPT in Most Patients!

Featured Lecture: New DAPT Duration Recommendations

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content